In 2022, The Asthma Treatment Market size amounted to USD 20.4 Billion & is estimated to reach USD 29.45 Billion by 2030 and increase at a compound annual growth rate of 4.7% between 2023 and 2030.
The Asthma Treatment Market refers to the pharmaceutical and medical devices sector focused on providing treatment and management solutions for individuals with asthma. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms like wheezing, shortness of breath, coughing, and chest tightness. The goal of asthma treatment is to control symptoms, prevent exacerbations, and improve patients' quality of life. The asthma treatment market encompasses various products and therapies, including, Inhalers are the most common and effective way to deliver asthma medications directly to the lungs. They come in different types, such as short-acting bronchodilators (relievers) to provide quick relief during asthma attacks and long-acting bronchodilators (controllers) to maintain asthma control over time. Nebulizers are devices that convert liquid medications into a fine mist that patients can inhale through a mask or mouthpiece. They are often used for young children, elderly individuals, or those who have difficulty using inhalers. Corticosteroids: Inhaled corticosteroids (ICS) are a standard controller medication used to reduce airway inflammation and prevent asthma symptoms.
.png)
They are considered one of the most effective long-term asthma treatments. LABAs are bronchodilators that work by relaxing and opening the airways. They are often used in combination with ICS to provide better asthma control. Biologic therapies are a newer class of medications that target specific immune pathways involved in severe asthma. They are used for patients with severe asthma who do not respond well to traditional treatments. Allergy Immunotherapy For patients with allergic asthma triggered by allergens, allergy immunotherapy (allergy shots or sublingual tablets) can help reduce sensitivity and asthma symptoms. The asthma treatment market is driven by the increasing prevalence of asthma globally, rising awareness about the disease, and advancements in medical research and technology. Companies in this market invest in research and development to develop innovative therapies and improve the delivery of existing treatments. As with any medical market, the asthma treatment market is subject to regulatory requirements, safety considerations, and competitive forces. The availability and accessibility of asthma treatments may vary in different regions due to healthcare systems, reimbursement policies, and local market dynamics.
DRIVERS:
The prevalence of asthma has been steadily rising worldwide.
Growing Awareness and Diagnosis is the main driver of the Asthma Treatment Market.
Increased awareness about asthma and its symptoms among patients and healthcare providers has led to more timely and accurate diagnoses. As a result, more individuals are seeking medical attention and appropriate treatment for asthma.
RESTRAIN:
Despite major advances in asthma therapy, there is currently no cure.
Low Treatment Compliance is a huge restraint of the Asthma Treatment Market.
Asthma treatment requires consistent and long-term management, including daily medication use and trigger avoidance. However, many patients struggle with treatment adherence due to various factors, such as forgetfulness, difficulty using inhalers, side effects, and perceived improvement leading to treatment discontinuation. Poor compliance can hinder treatment effectiveness and disease control.
OPPORTUNITY:
Biologic therapies have shown promise in treating severe asthma by targeting specific inflammatory pathways.
The biggest potential in the Asthma Treatment Market is Digital Health Solutions.
The integration of digital health technologies, such as smart inhalers, mobile apps, and telemedicine platforms, offers opportunities for better asthma management and patient engagement. These tools can help monitor adherence, track symptoms, and provide personalized treatment plans.
CHALLENGES:
Ensuring consistent and long-term treatment adherence is a significant challenge in asthma management.
The Asthma Treatment Market has significant obstacles due to a lack of curative options.
While asthma can be effectively managed, there is currently no cure for the disease. The absence of a curative treatment option makes long-term management essential, and some patients may still experience symptoms and exacerbations despite appropriate treatment.
The Russian invasion of Ukraine has resulted in horrific human misery and, as a result, the largest broad economic boycott of a belligerent nation in contemporary history. The treatment of life-threatening illnesses caused by unusual circumstances caused by the ongoing military war. Ukraine has 42-45 million of patients who require long-term therapy for hypertension, diabetes, asthma, COPD, and a variety of other chronic disorders that, owing to their enormous prevalence, are of the utmost importance to public health. Ukraine contributes to the testing of hundreds of clinical studies each year through the US Food and Drug Administration's clinical trial database. More significantly, Ukraine has been a prominent provider of medicinal chemistry services, such as the synthesis and optimisation of physiologically active drug molecules, commercially available reagents including drug building blocks, and chemical libraries. The Ukrainian research services use pertains to the creation and synthesis of innovative medicinal substances that use their chemical building blocks to develop new medication molecules. The asthma treatment market grain less profit because of this conflict the supply chain is down uptown 3-4%
IMPACT OF ONGOING RECESSION
Chronic respiratory illnesses, particularly chronic obstructive pulmonary disease (COPD) and asthma are among the main causes of death and morbidity globally. According to the Global Burden of Disease Studies in 2020, COPD and asthma were among the top 20 diseases causing disability globally, ranking 8th and 23rd in terms of disease burden when evaluated by disability-adjusted life years, respectively. Bronchial asthma is the most prevalent chronic respiratory condition, with an estimated 368.2 million cases in 2020. Around 1.12 million individuals died from asthma in 2020, a drop of 27.2% from 2002, while the age-standardized mortality rate fell by 58%. Asthma prevalence grew by 13.2%, but age-standardized prevalence fell by 18.3%. In the ongoing recession, the asthma treatment market is an increase its product & service prices up to 5-7%.
By Treatment
Long-Term Control Medications
Quick-Relief Medications
By Route of Administration
Injectable
Inhaled
Oral
By Distribution Channel
Online Pharmacies
Retail Pharmacies & Drug Stores
Hospital Pharmacies
.png)
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSIS
North America: The North American market is characterised by a high incidence of asthma as well as increased knowledge of sophisticated and effective asthma therapies. These factors, along with increased patient awareness of new and emerging therapeutic options, the region's strong market growth potential due to underdiagnosis of asthmatic patients, and the presence of major biopharmaceutical companies and their strong product offerings, are responsible for the region's dominant share of the global market.
Asia Pacific: The Asia-Pacific market is expected to have a greater CAGR. The increasing presence of key products in the region is expected to drive demand for asthma drugs during the forecast period. The growth of Pulmicort, a key asthma drug, in the region, was driven by a positive performance in China, and this, combined with the presence of a large and underpenetrated market in the region, is expected to drive market growth in Asia Pacific during the forecast period.
Some major key players in Asthma Treatment Market are AstraZeneca, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline pic, Sanofi, Mylan N.V., Genentech, Inc. (F. Hoffmann-La Roche Ltd), Regeneron, Novartis AG and other players.
In 2021: Cipla Inc. reported the successful completion of a phase Ill clinical research of fluticasone propionate and salmeterol inhalation powder, a generic asthma medication approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The generic version of Advair Diskus 100/50 mcg is this pipeline candidate.
In 2021: The FDA issued regulatory clearance for Cipla's generic asthma inhaler, the generic version of the albuterol inhaler, in response to asthma drug shortages caused by the COVID-19 crisis. This medicine is frequently used as a rescue therapy for asthmatic patients.
In 2020: The FDA approved AstraZeneca's asthma medication Fasenra for self-administration in the United States.
| Report Attributes | Details |
| Market Size in 2022 | US$ 20.4 Bn |
| Market Size by 2030 | US$ 29.45 Bn |
| CAGR | CAGR of 4.7 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Long-Term Control Medications and Quick-Relief Medications) • By Route of Administration (Injectable, Inhaled, and Oral) • By Distribution Channel (Online Pharmacies, Retail Pharmacies & Drug Stores, Hospital Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | AstraZeneca, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline pic, Sanofi, Mylan N.V., Genentech, Inc. (F. Hoffmann-La Roche Ltd), Regeneron, Novartis AG |
| Key Drivers | • The prevalence of asthma has been steadily rising worldwide. • Growing Awareness and Diagnosis is the main driver of the Asthma Treatment Market. |
| Market Restraints | • Despite major advances in asthma therapy, there is currently no cure. • Low Treatment Compliance is a huge restraint of the Asthma Treatment Market. |
Ans. The compound annual growth rate for Asthma Treatment Market for the forecast period is 4.7%.
Ans. In 2023, the injectable medication delivery market is expected to be valued at 20.4 billion USD.
Ans. Adoption of combination treatment is increasing, as is the prevalence of asthma.
Ans. The market for Asthma Treatment is anticipated to be worth USD 29.45 Billion by 2030.
Ans. North America is estimated to account for the majority of the market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Asthma Treatment Market Segmentation, By Treatment
8.1 Long-Term Control Medications
8.2 Quick-Relief Medications
9. Asthma Treatment Market Segmentation, By Route of Administration
9.1 Injectable
9.2 Inhaled
9.3 Oral
10. Asthma Treatment Market Segmentation, By Distribution Channel
10.1 Online Pharmacies
10.2 Retail Pharmacies & Drug Stores
10.3 Hospital Pharmacies
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Asthma Treatment Market by Country
11.2.2 North America Asthma Treatment Market by Treatment
11.2.3 North America Asthma Treatment Market by Route of Administration
11.2.4 North America Asthma Treatment Market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Asthma Treatment Market by Treatment
11.2.5.2 USA Asthma Treatment Market by Route of Administration
11.2.5.3 USA Asthma Treatment Market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Asthma Treatment Market by Treatment
11.2.6.2 Canada Asthma Treatment Market by Route of Administration
11.2.6.3 Canada Asthma Treatment Market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Asthma Treatment Market by Treatment
11.2.7.2 Mexico Asthma Treatment Market by Route of Administration
11.2.7.3 Mexico Asthma Treatment Market by Distribution Channel
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Asthma Treatment Market by Country
11.3.1.2 Eastern Europe Asthma Treatment Market by Treatment
11.3.1.3 Eastern Europe Asthma Treatment Market by Route of Administration
11.3.1.4 Eastern Europe Asthma Treatment Market by Distribution Channel
11.3.1.5 Poland
11.3.1.5.1 Poland Asthma Treatment Market by Treatment
11.3.1.5.2 Poland Asthma Treatment Market by Route of Administration
11.3.1.5.3 Poland Asthma Treatment Market by Distribution Channel
11.3.1.6 Romania
11.3.1.6.1 Romania Asthma Treatment Market by Treatment
11.3.1.6.2 Romania Asthma Treatment Market by Route of Administration
11.3.1.6.4 Romania Asthma Treatment Market by Distribution Channel
11.3.1.7 Turkey
11.3.1.7.1 Turkey Asthma Treatment Market by Treatment
11.3.1.7.2 Turkey Asthma Treatment Market by Route of Administration
11.3.1.7.3 Turkey Asthma Treatment Market by Distribution Channel
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Asthma Treatment Market by Treatment
11.3.1.8.2 Rest of Eastern Europe Asthma Treatment Market by Route of Administration
11.3.1.8.3 Rest of Eastern Europe Asthma Treatment Market by Distribution Channel
11.3.2 Western Europe
11.3.2.1 Western Europe Asthma Treatment Market by Country
11.3.2.2 Western Europe Asthma Treatment Market by Treatment
11.3.2.3 Western Europe Asthma Treatment Market by Route of Administration
11.3.2.4 Western Europe Asthma Treatment Market by Distribution Channel
11.3.2.5 Germany
11.3.2.5.1 Germany Asthma Treatment Market by Treatment
11.3.2.5.2 Germany Asthma Treatment Market by Route of Administration
11.3.2.5.3 Germany Asthma Treatment Market by Distribution Channel
11.3.2.6 France
11.3.2.6.1 France Asthma Treatment Market by Treatment
11.3.2.6.2 France Asthma Treatment Market by Route of Administration
11.3.2.6.3 France Asthma Treatment Market by Distribution Channel
11.3.2.7 UK
11.3.2.7.1 UK Asthma Treatment Market by Treatment
11.3.2.7.2 UK Asthma Treatment Market by Route of Administration
11.3.2.7.3 UK Asthma Treatment Market by Distribution Channel
11.3.2.8 Italy
11.3.2.8.1 Italy Asthma Treatment Market by Treatment
11.3.2.8.2 Italy Asthma Treatment Market by Route of Administration
11.3.2.8.3 Italy Asthma Treatment Market by Distribution Channel
11.3.2.9 Spain
11.3.2.9.1 Spain Asthma Treatment Market by Treatment
11.3.2.9.2 Spain Asthma Treatment Market by Route of Administration
11.3.2.9.3 Spain Asthma Treatment Market by Distribution Channel
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands Asthma Treatment Market by Treatment
11.3.2.10.2 Netherlands Asthma Treatment Market by Route of Administration
11.3.2.10.3 Netherlands Asthma Treatment Market by Distribution Channel
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland Asthma Treatment Market by Treatment
11.3.2.11.2 Switzerland Asthma Treatment Market by Route of Administration
11.3.2.11.3 Switzerland Asthma Treatment Market by Distribution Channel
11.3.2.1.12 Austria
11.3.2.12.1 Austria Asthma Treatment Market by Treatment
11.3.2.12.2 Austria Asthma Treatment Market by Route of Administration
11.3.2.12.3 Austria Asthma Treatment Market by Distribution Channel
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe Asthma Treatment Market by Treatment
11.3.2.13.2 Rest of Western Europe Asthma Treatment Market by Route of Administration
11.3.2.13.3 Rest of Western Europe Asthma Treatment Market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia-Pacific Asthma Treatment Market by Country
11.4.2 Asia-Pacific Asthma Treatment Market by Treatment
11.4.3 Asia-Pacific Asthma Treatment Market by Route of Administration
11.4.4 Asia-Pacific Asthma Treatment Market by Distribution Channel
11.4.5 China
11.4.5.1 China Asthma Treatment Market by Treatment
11.4.5.2 China Asthma Treatment Market by Route of Administration
11.4.5.3 China Asthma Treatment Market by Distribution Channel
11.4.6 India
11.4.6.1 India Asthma Treatment Market by Treatment
11.4.6.2 India Asthma Treatment Market by Route of Administration
11.4.6.3 India Asthma Treatment Market by Distribution Channel
11.4.7 japan
11.4.7.1 Japan Asthma Treatment Market by Treatment
11.4.7.2 Japan Asthma Treatment Market by Route of Administration
11.4.7.3 Japan Asthma Treatment Market by Distribution Channel
11.4.8 South Korea
11.4.8.1 South Korea Asthma Treatment Market by Treatment
11.4.8.2 South Korea Asthma Treatment Market by Route of Administration
11.4.8.3 South Korea Asthma Treatment Market by Distribution Channel
11.4.9 Vietnam
11.4.9.1 Vietnam Asthma Treatment Market by Treatment
11.4.9.2 Vietnam Asthma Treatment Market by Route of Administration
11.4.9.3 Vietnam Asthma Treatment Market by Distribution Channel
11.4.10 Singapore
11.4.10.1 Singapore Asthma Treatment Market by Treatment
11.4.10.2 Singapore Asthma Treatment Market by Route of Administration
11.4.10.3 Singapore Asthma Treatment Market by Distribution Channel
11.4.11 Australia
11.4.11.1 Australia Asthma Treatment Market by Treatment
11.4.11.2 Australia Asthma Treatment Market by Route of Administration
11.4.11.3 Australia Asthma Treatment Market by Distribution Channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Asthma Treatment Market by Treatment
11.4.12.2 Rest of Asia-Pacific Asthma Treatment Market by Route of Administration
11.4.12.3 Rest of Asia-Pacific Asthma Treatment Market by Distribution Channel
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Asthma Treatment Market by Country
11.5.1.2 Middle East Asthma Treatment Market by Treatment
11.5.1.3 Middle East Asthma Treatment Market by Route of Administration
11.5.1.4 Middle East Asthma Treatment Market by Distribution Channel
11.5.1.5 UAE
11.5.1.5.1 UAE Asthma Treatment Market by Treatment
11.5.1.5.2 UAE Asthma Treatment Market by Route of Administration
11.5.1.5.3 UAE Asthma Treatment Market by Distribution Channel
11.5.1.6 Egypt
11.5.1.6.1 Egypt Asthma Treatment Market by Treatment
11.5.1.6.2 Egypt Asthma Treatment Market by Route of Administration
11.5.1.6.3 Egypt Asthma Treatment Market by Distribution Channel
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Asthma Treatment Market by Treatment
11.5.1.7.2 Saudi Arabia Asthma Treatment Market by Route of Administration
11.5.1.7.3 Saudi Arabia Asthma Treatment Market by Distribution Channel
11.5.1.8 Qatar
11.5.1.8.1 Qatar Asthma Treatment Market by Treatment
11.5.1.8.2 Qatar Asthma Treatment Market by Route of Administration
11.5.1.8.3 Qatar Asthma Treatment Market by Distribution Channel
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Asthma Treatment Market by Treatment
11.5.1.9.2 Rest of Middle East Asthma Treatment Market by Route of Administration
11.5.1.9.3 Rest of Middle East Asthma Treatment Market by Distribution Channel
11.5.2 Africa
11.5.2.1 Africa Asthma Treatment Market by Country
11.5.2.2 Africa Asthma Treatment Market by Treatment
11.5.2.3 Africa Asthma Treatment Market by Route of Administration
11.5.2.4 Africa Asthma Treatment Market by Distribution Channel
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Asthma Treatment Market by Treatment
11.5.2.5.2 Nigeria Asthma Treatment Market by Route of Administration
11.5.2.5.3 Nigeria Asthma Treatment Market by Distribution Channel
11.5.2.6 South Africa
11.5.2.6.1 South Africa Asthma Treatment Market by Treatment
11.5.2.6.2 South Africa Asthma Treatment Market by Route of Administration
11.5.2.6.3 South Africa Asthma Treatment Market by Distribution Channel
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Asthma Treatment Market by Treatment
11.5.2.7.2 Rest of Africa Asthma Treatment Market by Route of Administration
11.5.2.7.3 Rest of Africa Asthma Treatment Market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Asthma Treatment Market by Country
11.6.2 Latin America Asthma Treatment Market by Treatment
11.6.3 Latin America Asthma Treatment Market by Route of Administration
11.6.4 Latin America Asthma Treatment Market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil America Asthma Treatment Market by Treatment
11.6.5.2 Brazil America Asthma Treatment Market by Route of Administration
11.6.5.3 Brazil America Asthma Treatment Market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina America Asthma Treatment Market by Treatment
11.6.6.2 Argentina America Asthma Treatment Market by Route of Administration
11.6.6.3 Argentina America Asthma Treatment Market by Distribution Channel
11.6.7 Colombia
11.6.7.1 Colombia America Asthma Treatment Market by Treatment
11.6.7.2 Colombia America Asthma Treatment Market by Route of Administration
11.6.7.3 Colombia America Asthma Treatment Market by Distribution Channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Asthma Treatment Market by Treatment
11.6.8.2 Rest of Latin America Asthma Treatment Market by Route of Administration
11.6.8.3 Rest of Latin America Asthma Treatment Market by Distribution Channel
12 Company profile
12.1 AstraZeneca
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Teva Pharmaceutical Industries Ltd
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Merck & Co., Inc
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Boehringer Ingelheim International GmbH
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 GlaxoSmithKline pic
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Mylan N.V.
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Genentech, Inc. (F. Hoffmann-La Roche Ltd)
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Regeneron
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Novartis AG
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Breast Imaging Market size was estimated USD 0.17 billion in 2022 and is expected to reach USD 0.28 billion by 2030 at a CAGR of 6.8% during the forecast period of 2023-2030.
The Canada Medical Isotope market size for Canada was valued at USD 911.17 million in 2022 and is expected to reach USD 2223.99 million in 2031 and grow at a CAGR of 11.8% over the forecast period of 2024-2031.
The Genome Editing Market size was estimated USD 6.4 billion in 2022 and is expected to reach USD 23.8 billion by 2030 at a CAGR of 17.9% during the forecast period of 2023-2030.
The Omega 3 supplements market was valued USD 6.60 billion in 2022 and is estimated to reach USD 12.96 billion by 2030. From 2023 to 2030 & grow at a CAGR of 8.8%.
The Medical Coding Market Size was valued at USD 20.83 Billion in 2022, and is expected to reach USD 48.35 Billion by 2030, and grow at a CAGR of 11.1% over the forecast period 2023-2030.
The Circulating Tumor Cells Market size was estimated USD 10.4 billion in 2022 and is expected to reach USD 28.4 billion by 2030 at a CAGR of 13.4% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
